Levetiracetam
Product Images NDC 50090-4023

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 50090-4023). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label Image (Lbl500904023)

Label Image (Lbl500904023)
Levetiracetam is a medication available in a tablet form. Each tablet contains 1 gram of the active ingredient. This particular package contains 50 tablets with a total of 1600 milligrams.*
FDA Label Image

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)
The figure shows responder rates in Study 1, with a 250% reduction from baseline. The percentage values range from 0% to 39.6%, and there is a statistical significance when compared with the placebo. The rest of the text contains non-English characters and cannot be used to form a description.*
FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)
The text describes a figure, specifically Figure 2, which shows the Responder Rate in Study 2 during a certain period called Period A. The figure displays the percentage of patients who showed a reduction of 250% from the baseline. The percentage of patients who responded is given for three treatment groups: Placebo (N=111), Levetiracetam 1000 mg/day (N=106), and Levetiracetam 2000 mg/day (N=105). One of the percentages is statistically significant versus placebo.*
FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)
FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)
The figure shows the responder rate (50% reduction from baseline) in Study 4. The placebo group (N=97) had a responder rate of 19.6%, while the levetiracetam group (N=101) had a significantly higher responder rate of 44.6%. The value for the responder rate in the levetiracetam group is 45%, and there is a statistically significant difference between the levetiracetam and placebo groups.*
FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)
The figure shows the responder rate of patients aged 1 month to <4 years in Study 5, indicating >50% reduction from baseline. The graph compares the results of patients administered with Levetiracetam and Placebo. The percentage of patients who responded to the treatment is plotted on the Y-axis, while the type of treatment (Levetiracetam or Placebo) is plotted on the X-axis. The results show that Levetiracetam was statistically significant in reducing the rate of responders compared to Placebo.*
FDA Label Image

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)
The text describes a graph or figure showing the Responder Rate in percentage for patients suffering from PGTC Seizure Frequency per Week. The Responder Rate has been reduced by 250% from Baseline. The study included a Placebo group with 84 patients and a Levetiracetam group with 79 patients. The graph shows that the Levetiracetam group had a statistically significant better response rate as compared to the Placebo group.*
FDA Label Image

Chemical Structure (Levetiracetam Str)

Chemical Structure (Levetiracetam Str)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.